4.5 Editorial Material

Failure to use new breakthrough treatments for epilepsy

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Clinical Neurology

Cost-effectiveness of cenobamate for focal seizures in people with drug-resistant epilepsy

Vicki Laskier et al.

Summary: This study aimed to estimate the cost-effectiveness of add-on cenobamate in the UK for treating drug-resistant focal seizures in adults. The results showed that cenobamate was cost-saving and led to improved quality-adjusted life-years compared to other antiseizure medications.

EPILEPSIA (2023)

Article Behavioral Sciences

Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain

Vicente Villanueva et al.

Summary: The study aims to compare the clinical and economic benefits of the new drug Cenobamate with existing third-generation Anti-Seizure Medications for patients with Drug-Resistant Epilepsy. Cenobamate shows superior efficacy and efficiency in the treatment of Focal-Onset Seizures.

EPILEPSY & BEHAVIOR (2023)

Article Public, Environmental & Occupational Health

Seizure- or Epilepsy-Related Emergency Department Visits Before and During the COVID-19 Pandemic — United States, 2019–2021

Sanjeeb Sapkota et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Article Clinical Neurology

Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures

Pavel Klein et al.

Summary: This study evaluated the long-term efficacy and safety of adjunctive cenobamate in the treatment of uncontrolled focal seizures. The results showed that cenobamate reduced seizure frequency and had a high retention rate over a 48-month period. No new safety concerns were identified. These findings highlight the potential clinical benefits of cenobamate in long-term management of patients with uncontrolled focal seizures.

NEUROLOGY (2022)

Article Health Care Sciences & Services

Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain

Miguel Angel Calleja et al.

Summary: This study aims to determine the economically justifiable price of cenobamate as a cost-effective alternative for the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain. The analysis concludes that cenobamate is cost-effective compared to other anti-seizure medications and provides additional clinical benefits.

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2022)

Article Clinical Neurology

Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study

Michael R. Sperling et al.

Summary: The long-term open-label study of adjunctive cenobamate showed high rates of sustained 100% and >=90% seizure reduction in patients with uncontrolled focal seizures, with many achieving response early during titration. These findings suggest durable seizure frequency reduction with cenobamate in adults.

EPILEPSIA (2021)

Article Clinical Neurology

Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome

J. Helen Cross et al.

Summary: This study found that the all-cause and SUDEP mortality rates in DS patients treated with FFA were lower than previously reported. Further studies are needed to confirm the impact of FFA on SUDEP risk and to explore the underlying mechanisms.

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2021)

Editorial Material Clinical Neurology

Highlights From AES2020, a Virtual American Epilepsy Society Experience

Barbara C. Jobst et al.

Summary: Despite the impossibility of holding an in-person meeting, the virtual event AES2020 was a great success with extensive educational content and discussions on various aspects of epilepsy, showcasing the latest research and advancements in the field.

EPILEPSY CURRENTS (2021)

Editorial Material Behavioral Sciences

Raising the bar: Fenfluramine sets new treatment standards for Dravet syndrome

Joseph Sullivan et al.

EPILEPSY & BEHAVIOR (2021)

Article Clinical Neurology

Suicidality Risk of Newer Antiseizure Medications A Meta-analysis

Pavel Klein et al.

Summary: This study analyzed the risk of suicidality for five antiseizure medications approved since 2008, finding no increased risk of suicidal ideation or attempts compared to placebo. Therefore, these medications do not warrant a class warning for suicidality.

JAMA NEUROLOGY (2021)

Review Clinical Neurology

Seizure freedom as an outcome in epilepsy treatment clinical trials

Jonathan J. Halford et al.

ACTA NEUROLOGICA SCANDINAVICA (2020)

Editorial Material Neurosciences

The feast and famine: Epilepsy treatment and treatment gaps in early 21st century

Wolfgang Loescher et al.

NEUROPHARMACOLOGY (2020)

Review Clinical Neurology

Recognizing and preventing epilepsy-related mortality A call for action

Orrin Devinsky et al.

NEUROLOGY (2016)

Article Clinical Neurology

Mortality in Dravet syndrome

Monica S. Cooper et al.

EPILEPSY RESEARCH (2016)

Article Clinical Neurology

A reappraisal of mortality after epilepsy surgery

Michael R. Sperling et al.

NEUROLOGY (2016)

Article Medicine, General & Internal

Early identification of refractory epilepsy.

P Kwan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2000)